Back to Areas of Study
Incyte is developing an IDO1 inhibitor.
IDO1 is an immunosuppressive enzyme that leads to regulatory T-cell generation and activation and allows tumors to escape from immune surveillance. Inhibition of immunomodulatory mechanisms with IDO1 inhibitor-based combination therapy may re-establish antitumor immunity.
Do you want to continue?